Home
English (United States)
|
Italiano (Italia)
Contacts
|
Rss
Search
Search
English (United States)
|
Italiano (Italia)
Home
Who we are
Mission and strategy
Structure and management
News and events
Press review
Farmindustria bulletin
Photo gallery
Video gallery
The group
Our offices
The group in figures
Activities
Research and development
Pre-clinical development
Clinical development
Clinical trial transparency
Medical affairs
Regulatory affairs
Scientific publications
Pre-clinical
Pre-approval
Post-approval
Pharmaceutical manufacturing
Business development
Licensing
Pipeline
About muscular distrophies
Duchenne and Becker MD
Givinostat
Mieloproliferative Neoplasms
Polycythemia Vera (PV)
Clinical trials
Givinostat for DMD
Givinostat for BMD - ITF BECKER
Givinostat for Polycythemia Vera (PV)
Therapeutic areas
Thrombosis and critical ischemia
Drugs
Food supplements
Cardio-metabolic area
Drugs
Food supplements
Immuno-oncology
Drugs
Gynecology
Drugs
Food supplements
Medical devices
Neurology and psychiatry
Drugs
Food supplements
Responsibilities
Pharmacovigilance
Patients association
Transparency
Safety policy
Organization
Home
Who we are
- Mission and strategy
- Structure and management
- News and events
- Press review
- Farmindustria bulletin
- Photo gallery
- Video gallery
The group
- Our offices
- The group in figures
Activities
- Research and development
- 
      - Pre-clinical development
- 
      - Clinical development
- 
      - Clinical trial transparency
- 
      - Medical affairs
- 
      - Regulatory affairs
- Scientific publications
- 
      - Pre-clinical
- 
      - Pre-approval
- 
      - Post-approval
- Pharmaceutical manufacturing
- Business development
- Licensing
- Pipeline
- 
      - About muscular distrophies
- 
      - 
      - Duchenne and Becker MD
- 
      - 
      - Givinostat
- 
      - Mieloproliferative Neoplasms
- 
      - 
      - Polycythemia Vera (PV)
- 
      - Clinical trials
- 
      - 
      - Givinostat for DMD
- 
      - 
      - Givinostat for BMD - ITF BECKER
- 
      - 
      - Givinostat for Polycythemia Vera (PV)
Therapeutic areas
- Thrombosis and critical ischemia
- 
      - Drugs
- 
      - Food supplements
- Cardio-metabolic area
- 
      - Drugs
- 
      - Food supplements
- Immuno-oncology
- 
      - Drugs
- Gynecology
- 
      - Drugs
- 
      - Food supplements
- 
      - Medical devices
- Neurology and psychiatry
- 
      - Drugs
- 
      - Food supplements
Responsibilities
- Pharmacovigilance
- Patients association
- Transparency
- Safety policy
Organization
Research, innovation, productive technology and international expansion
Strong and constant commitment to research
Productive technology according to the highest standards
Opening and consolidation on new international markets
At the service of human health
Italfarmaco
Italfarmaco is a private Italian multinational company located in Milan, operating in Italy and abroad in both the pharmaceutical and fine chemical industries...
Read more
Research and development
Italfarmaco is a concrete reality in the Italian pharmaceutical industry; it has been active in pharmaceutical research and development areas...
Read more
Manufacturing
The manufacturing meets the highest international quality standards: Italfarmaco is authorized by the Italian Medicines Agency (AIFA) to the manufacturing...
Read more
Drugs with high therapeutic value
Cardiovascular & osteoporosis
The drugs in this sector especially affect the cardiovascular area with particular attention to hypertension, osteoporosis and critical ischemia.
Immuno-oncology
The Immuno-Oncologic Therapeutic area of Italfarmaco is acknowledged by the Italian oncologic community as a reference point in the specialist sector thanks to the originality of its products, the innovative pharmaceutical solutions and the innovation of experimental protocols.
Thrombosis & critical ischemia
The activities in the field of prophylaxis, thrombosis and critical ischemia is strengthened by a long experience that comes with Calciparine, unfractionated heparin, and finds its evolution in Nadroparin Calcium, a low molecular weight heparin.
Gynecology
The commitment of Italfarmaco in the gynecological therapeutic area is aimed at the development of innovative and complete solutions studied for the different steps of a woman’s life, in relation to Anemia, Fertility, Pregnancy, Menopause, Gynecological Infection and inflammation area.
Neurology & psychiatry
The goal of this area is to provide physicians with solutions for still unmet therapeutic requirements for diseases of the Central Nervous System, thanks to the innovative ability in pharmaceutical technologies of our laboratories.
Duchenne Awareness DAY
7 September marks World Duchenne Awareness Day (WDAD), a disease in which we as a company are particularly involved. >
Press review
News and events
Business Wire
March 21, 2024
Italfarmaco receives FDA approval for givinostat in Duchenne muscular dystrophy (DMD)
Read more
Duchenne Awareness DAY
September 07, 2023
7 September marks World Duchenne Awareness Day (WDAD), a disease in which we as a company are particularly involved.
Read more
Farmindustria bullettin
Antibiotic-resistant bacterial infections
Read more
Media gallery
Photo gallery
Video gallery
Coronavirus disease (COVID – 19)
Measures taken by the Company for the safeguard of the health and safety of associates and patients.
Read more >
The ITF Group mosaic video
Everything will be all right: #noipervoi and #voipernoi
Contacts
Write an e-mail
Our offices
Submit your CV
Main offices
and factory
ITALFARMACO S.p.A.
V.le Fulvio Testi, 330
20126 Milan
Tel. 02 64431
Fax 02 644346 / 02 66102753
Direction,
offices and
research center
ITALFARMACO S.p.A.
Via dei Lavoratori, 54
20092 Cinisello Balsamo (MI)
Tel. 02 64431
Fax 02 6424790
Legal notes
Privacy policy
Cookie policy
Terms of use
© Copyright 2015-2024 by ITALFARMACO S.p.A. | all rights reserved | Revenue Number and VAT number 00737420158
Companies' Register of Milan R.E.A. 273567| Fully paid stock capital €13.000.000
Powered by